Abstracts tagged "Epidemiology"

Abstract Number: 1658 • ACR Convergence 2021
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Katherine Liao¹, Thany Seyok¹ and Lisa Cannon-Albright², ¹Brigham and Women's Hospital, Boston, MA, ²University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0430 • ACR Convergence 2021
Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
Brett Doliner¹, Karen Rodriguez¹, Sydney Montesi¹, Xiaoqing Fu¹, Amita Sharma¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: Despite treatment advances, ANCA-associated vasculitis (AAV) remains associated with excess morbidity and mortality. Interstitial lung disease (ILD) is an increasingly recognized manifestation of AAV…
Abstract Number: 0587 • ACR Convergence 2021
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Akhil Sood¹, Yong-Fang Kuo², Jordan Westra² and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for opioid use. Disease-modifying antirheumatic drugs (DMARDs) have led to better control of disease activity.…
Abstract Number: 0959 • ACR Convergence 2021
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
Celline Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen Ginzler⁸, Daniel Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Anne Dooley¹², Christine Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Soren Jacobsen¹⁷, S Sam Lim¹⁸, Ronald F van Vollenhoven¹⁹, Ola Nived²⁰, Andreas Jnsen²⁰, Diane Kamen²¹, Cynthia Aranow²², Guillermo Ruiz-Irastorza²³, Jorge Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R Fortin²⁶, Graciela Alarcn²⁷, Joan Merrill²⁸, Kenneth Kalunian²⁹, Manuel Ramos-Casals³⁰, Kristjan Steinsson³¹, Asad Zoma³², Anca Askanase³³, Munther Khamashta³⁴, Ian N. Bruce³⁵, Murat Inanc³⁶ and Sasha Bernatsky³⁷, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Northwestern University, Chicago, IL, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Hanyang University Medical Center, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹²Raleigh Neurology Associates, Chapel Hill, NC, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴Centre for Rheumatology, University College London, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Allegheny Health Network, Wexford, PA, ¹⁷Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁰Lund University, Lund, Sweden, ²¹Medical University of South Carolina, Charleston, SC, ²²Feinstein Institutes for Medical Research, Manhasset, NY, ²³Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁴University Health Network, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ²⁷University of Alabama at Birmingham, Birmingham, AL, ²⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁹UC San Diego, La Jolla, CA, ³⁰Hospital Clinic, Barcelona, Barcelona, Spain, ³¹National University Hospital of Iceland, Reykjavik, Iceland, ³²University of Glasgow, East Kilbride, United Kingdom, ³³Columbia University Medical Center, New York, NY, ³⁴King's College London, London, United Kingdom, ³⁵University of Manchester, Manchester, United Kingdom, ³⁶Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁷McGill University, Montréal, QC, Canada
Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…
Abstract Number: 1097 • ACR Convergence 2021
Gastrointestinal Malignancies in Sarcoidosis: A Nationwide Analysis
Rawish Fatima, Ashu Acharya, Saffa Iftikhar and Joan N Gekonde, University of Toledo Medical Center, Toledo, OH
Background/Purpose: Sarcoidosis is a multisystem disorder that can involve any organ system. It can involve organs like the lungs, skin, eyes, nose, muscles, heart, liver,…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 0116 • ACR Convergence 2021
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
Kaleb Michaud¹, Adam Cornish², Alison Freifeld¹, Patricia Katz³ and Kristin Wipfler², ¹University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
Abstract Number: 0479 • ACR Convergence 2021
A Novel Semi-automated Classifier of Radiographic Hip Osteoarthritis on DXA Scans Is Strongly Predictive of Pain, Clinical Diagnosis and Joint Replacement: Findings from 40,000 Participants in UK Biobank
Benjamin Faber¹, Raja Ebsim², Fiona Saunders³, Monika Frysz¹, Claudia Lindner², Jennifer Gregory³, Richard Aspden³, Nicholas Harvey⁴, George Davey Smith¹, Timothy Cootes² and Jon Tobias¹, ¹University of Bristol, Bristol, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University of Aberdeen, Aberdeen, United Kingdom, ⁴University of Southampton, Southampton, United Kingdom
Background/Purpose: Radiographic hip osteoarthritis (rHOA) is traditionally defined on hip or pelvic radiographs, using subjective methods such as Kellgren-Lawrence scoring. Associations between subjective rHOA measures…
Abstract Number: 0588 • ACR Convergence 2021
Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Milena Gianfrancesco¹, Jing Li¹, Clairissa Ja², Andrea Seet¹, Gabriela Schmajuk¹ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC Davis, San Francisco
Background/Purpose: Our understanding of how medications such as biologic disease modifying anti-rheumatic drugs and targeted small molecules (b/tsDMARDs) influence disease activity in RA is based…
Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: 1121 • ACR Convergence 2021
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper¹, Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski¹, Eric Wright¹, Craig Beck², Rebecca Robinson³, Edward Casey⁴, Jerry A. Hall³ and Patricia Schepman⁴, ¹Geisinger, Danville, PA, ²Pfizer, Inc., London, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer, Inc., New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease with complex pathogenesis, and it is important to understand a patient's level of severity in order to plan and…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…
Abstract Number: 0480 • ACR Convergence 2021
Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
Martin Englund¹, Dorte Grønne², Ewa Roos², Søren Skou² and Aleksandra Turkiewicz¹, ¹Lund University, Lund, Sweden, ²University of Southern Denmark, Odense, Denmark
Background/Purpose: Patients who enroll in interventions are likely to do so when they experience a flare-up in symptoms. This may create issues in interpretation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].